Skip to main content
ISTH 2023 Main banner
Back

    Michael Wallisch, PhD (he/him/his)

    Principal Scientist
    Aronora, Inc.
    Portland, Oregon, United States

    Michael Wallisch, Ph.D., is a Principal Scientist at Aronora Biopharmaceuticals, Inc. in Portland, Oregon. He received his Ph.D. in biochemistry and toxicology from the Julius Maximilian University of Würzburg in Bavaria, Germany, studying proteins that regulate the termination of DNA replication.
    During his postdoctoral fellowship at Oregon Health & Science University, Dr. Wallisch first gained experience developing antibodies while focused on identifying and characterizing proteins involved in Fanconi anemia, a rare genetic disorder caused by a defect in DNA replication that primarily affects the bone marrow.
    After completing an NIH research project on the effects of maternal opioid use during gestation and its effect on the respiratory function of the fetus and neonate, he led the respiratory animal studies for a DARPA-funded study to develop a slow-release, self-regulating formulation of morphine that could be safely administered in the battlefield.
    Dr. Wallisch joined Aronora in 2012 and is the leading scientist for all non-human primate studies conducted with a unique arterio-venous shunt model in baboons, which the company utilizes for its pre-clinical and clinical drug candidates and in collaboration with other companies and scientists. He also leads a program developing and commercializing novel and safe antibodies targeting Factor XII for blood diseases with significant unmet medical needs.

    Presentation(s):